High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer

Aleksandra Sokolowska-Wedzina1, Grzegorz Chodaczek2, Julia Chudzian1

  • 1Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.

Insights

Researchers developed a novel antibody fragment targeting Fibroblast Growth Factor Receptor 1 (FGFR1) for lung cancer. This antibody delivers cytotoxic drugs specifically to FGFR1-positive cancer cells, offering a new immuno-oncology approach.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Targeted drug delivery via antibodies against tumor antigens is key in immuno-oncology.
  • Fibroblast Growth Factor Receptor 1 (FGFR1) is a targetable oncogene in smoking-associated lung cancers, particularly squamous cell carcinoma.

Purpose of the Study:

  • To generate a potent, fully human antibody fragment targeting FGFR1 for potential therapeutic applications.
  • To characterize the antibody's affinity, specificity, and internalization in cancer cells.

Main Methods:

  • Antibody phage display was used to select high-affinity single-chain variable fragments (scFv) against FGFR1.
  • Enzyme immunoassay (ELISA) and surface plasmon resonance (SPR) were employed for screening and characterization.
  • Confocal microscopy assessed cellular internalization, and payload delivery was tested in FGFR1-amplified lung cancer cells.

Main Results:

  • A high-affinity antibody fragment (D2) targeting FGFR1 was generated, with dissociation constants as low as 0.59 nmol/L for the scFvD2-Fc format.
  • The antibody demonstrated exquisite selectivity for FGFR1 over other family members and bound even in the presence of FGF2.
  • The scFvD2-Fc fragment was rapidly internalized by FGFR1-overexpressing cells and delivered cytotoxic payloads effectively.

Conclusions:

  • A highly specific, internalizing antibody fragment targeting FGFR1 has been developed.
  • This antibody fragment shows promise as a therapeutic agent for targeted delivery of cytotoxic drugs to FGFR1-positive lung cancer cells.

Related Concept Videos